News

The trial was based on age (men= 50 and women= 60), high-sensitivity C-reactive protein (hsCRP) = 2mg/l, and the presence of at least one additional CVD risk factor,

Ligon is expected to apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Patrick Kleyn, CEO of

The approval for Prezista was based on data from the Delphi trial. In the open-label, Phase 2 trial, the pharmacokinetics, safety, tolerability and efficacy of Prezista dosed twice

The FDA indicated that it intends to reschedule the meeting as soon as it can determine a schedule that will allow them to reconvene the advisory panel. This

LIPO-102 is a new, minimally-invasive, non-ablative approach to localised fat reduction comprising an injectable aqueous combination of salmeterol xinafoate (SX) and fluticasone propionate (FP). Reportedly, the Phase I

A paper entitled ‘A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy’, has been published online ahead of print in Ophthalmology. This publication

Labetalol HCl Injection is the generic equivalent of Prometheus Laboratories’ Trandate (Labetalol HCl) Injection. Labetalol HCl Injection is an adrenergic receptor blocking agent that has both selective alpha1-adrenergic

Millipore’s current research with BDI is focused on developing new technology platforms for in-process testing and real-time monitoring in biopharmaceutical manufacturing. Dennis Harris, chief scientific officer at Millipore,

The license agreement covers intellectual property rights for AMD-related genetic variants that have been confirmed in multiple clinical studies around the world. The portfolio of intellectual property being